{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:00:05Z","timestamp":1773093605479,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Teva Branded Pharmaceutical Products, R&D, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s41030-017-0041-7","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T02:24:27Z","timestamp":1493000667000},"page":"187-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ipratropium\/Salbutamol Comparator Versus Originator for Chronic Obstructive Pulmonary Disease Exacerbations: USA Observational Cohort Study Using the Clinformatics\u2122 Health Claims Database"],"prefix":"10.1007","volume":"3","author":[{"given":"Vicky","family":"Thomas","sequence":"first","affiliation":[]},{"given":"Eran","family":"Gefen","sequence":"additional","affiliation":[]},{"given":"Gokul","family":"Gopalan","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Mares","sequence":"additional","affiliation":[]},{"given":"Rosie","family":"McDonald","sequence":"additional","affiliation":[]},{"given":"Simon","family":"Wan Yau Ming","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-9992","authenticated-orcid":false,"given":"David B.","family":"Price","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"41_CR1","unstructured":"Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2016 [cited 2016 Aug 25]. http:\/\/www.goldcopd.org\/Guidelines\/guidelines-resources.html ."},{"key":"41_CR2","unstructured":"World Health Organization. World Health Statistics, 2008. 2008 [cited 2016 Aug 25]. http:\/\/www.who.int\/gho\/publications\/world_health_statistics\/EN_WHS08_Full.pdf ."},{"key":"41_CR3","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.","journal-title":"PLoS Med"},{"key":"41_CR4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","volume":"187","author":"J Vestbo","year":"2013","unstructured":"Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"41_CR5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.18553\/jmcp.2015.21.7.575","volume":"21","author":"AA Dalal","year":"2015","unstructured":"Dalal AA, Patel J, D\u2019Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Spec Pharm. 2015;21:575\u201383.","journal-title":"J Manag Care Spec Pharm"},{"key":"41_CR6","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.2147\/COPD.S90148","volume":"10","author":"AD Dhamane","year":"2015","unstructured":"Dhamane AD, Moretz C, Zhou Y, et al. COPD exacerbation frequency and its association with health care resource utilization and costs. Int J Chron Obstruct Pulmon Dis. 2015;10:2609\u201318.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"41_CR7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/15412555.2010.481697","volume":"7","author":"EL Toy","year":"2010","unstructured":"Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7:214\u201328.","journal-title":"COPD."},{"key":"41_CR8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.amjms.2016.06.006","volume":"353","author":"JE Burchette","year":"2017","unstructured":"Burchette JE, Campbell GD, Geraci SA. Preventing hospitalizations from acute exacerbations of chronic obstructive pulmonary disease. Am J Med Sci. 2017;353:31\u201340.","journal-title":"Am J Med Sci"},{"key":"41_CR9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1378\/chest.14-1677","volume":"147","author":"GJ Criner","year":"2015","unstructured":"Criner GJ, Bourbeau J, Diekemper RL, et al. Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:883\u201393.","journal-title":"Chest"},{"key":"41_CR10","unstructured":"Teva Pharmaceuticals USA. Ipratropium bromide and albuterol sulfate\u2014ipratropium bromide and albuterol sulfate solution [prescribing information]. 2016 [cited 2016 Aug 25]. http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=afcf38bf-b183-4569-b43f-25deb97f6693 ."},{"key":"41_CR11","unstructured":"Dey Pharma L.P. DuoNeb\u00ae (ipratropium bromide 0.5\u00a0mg\/albuterol sulfate 3.0\u00a0mg) Inhalation Solution [prescribing information]. Napa, CA: Dey Pharma L.P.; 2012."},{"key":"41_CR12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4137\/CCRPM.S7211","volume":"7","author":"S Ejiofor","year":"2013","unstructured":"Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med. 2013;7:17\u201334.","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"41_CR13","unstructured":"Norton Healthcare, T\/A IVAX Pharmaceuticals. Ipramol Steri-Neb 0.5\u00a0mg\/2.5\u00a0mg per 2.5\u00a0ml nebuliser solution [prescribing information]. West Yorkshire, UK: Norton Healthcare Ltd T\/A IVAX Pharmaceuticals UK; 2014."},{"key":"41_CR14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425251003649549","volume":"6","author":"J Gordon","year":"2010","unstructured":"Gordon J, Panos RJ. Inhaled albuterol\/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2010;6:381\u201392.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"41_CR15","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1378\/chest.105.5.1411","volume":"105","author":"COMBIVENT Inhalation Aerosol Study Group","year":"1994","unstructured":"COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994;105:1411\u20139.","journal-title":"Chest"},{"issue":"suppl 2","key":"41_CR16","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1513\/AnnalsATS.201309-300RM","volume":"11","author":"N Roche","year":"2014","unstructured":"Roche N, Reddel H, Martin R, et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc. 2014;11(suppl 2):S99\u2013104.","journal-title":"Ann Am Thorac Soc."},{"key":"41_CR17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"41_CR18","unstructured":"Rigazio A, Buck P, Lepore M, Burden A, Gilchrist A, von Ziegenweidt J, et al. Integration of dose-counters into metered-dose rescue inhalers may reduce incidence of respiratory-related emergency department visits. In: Presented at the 2013 annual meeting of the American College of Asthma, Allergy and Immunology; November 7\u201311, 2013; Baltimore, MD."},{"key":"41_CR19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","volume":"21","author":"W Szafranski","year":"2003","unstructured":"Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74\u201381.","journal-title":"Eur Respir J"},{"key":"41_CR20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","volume":"22","author":"PM Calverley","year":"2003","unstructured":"Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912\u20139.","journal-title":"Eur Respir J"},{"key":"41_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.rmed.2004.03.026","volume":"99","author":"K Herland","year":"2005","unstructured":"Herland K, Akselsen JP, Skjonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger \u201creal life\u201d population of patients with obstructive lung disease? Respir Med. 2005;99:11\u20139.","journal-title":"Respir Med"},{"key":"41_CR22","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2213-2600(13)70199-1","volume":"1","author":"N Roche","year":"2013","unstructured":"Roche N, Reddel HK, Agusti A, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med. 2013;1:e29\u201330.","journal-title":"Lancet Respir Med"},{"key":"41_CR23","doi-asserted-by":"crossref","first-page":"b81","DOI":"10.1136\/bmj.b81","volume":"338","author":"RL Tannen","year":"2009","unstructured":"Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ. 2009;338:b81.","journal-title":"BMJ"},{"key":"41_CR24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/COPD.S36997","volume":"7","author":"MK Pasquale","year":"2012","unstructured":"Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757\u201364.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"41_CR25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3111\/13696998.2011.576295","volume":"14","author":"AP Yu","year":"2011","unstructured":"Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011;14:315\u201323.","journal-title":"J Med Econ"},{"key":"41_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/COPD.S54417","volume":"9","author":"YS Punekar","year":"2014","unstructured":"Punekar YS, Shukla A, Mullerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9:65\u201373.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"41_CR27","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2147\/COPD.S106160","volume":"11","author":"G Hillas","year":"2016","unstructured":"Hillas G, Perlikos F, Tzanakis N. Acute exacerbation of COPD: is it the \u201cstroke of the lungs\u201d? Int J Chron Obstruct Pulmon Dis. 2016;11:1579\u201386.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"41_CR28","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","volume":"67","author":"S Suissa","year":"2012","unstructured":"Suissa S, Dell\u2019Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957\u201363.","journal-title":"Thorax"},{"key":"41_CR29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4187\/respcare.04597","volume":"62","author":"I Torres-Sanchez","year":"2017","unstructured":"Torres-Sanchez I, Cabrera-Martos I, Diaz-Pelegrina A, Valenza-Demet G, Moreno-Ramirez MP, Valenza MC. Physical and functional impairment during and after hospitalization in subjects with severe COPD exacerbation. Respir Care. 2017;62:209\u201314.","journal-title":"Respir Care"},{"key":"41_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1183\/09059180.00002610","volume":"19","author":"A Anzueto","year":"2010","unstructured":"Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19:113\u20138.","journal-title":"Eur Respir Rev"},{"key":"41_CR31","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1378\/chest.112.6.1514","volume":"112","author":"The COMBIVENT Inhalation Solution Study Group","year":"1997","unstructured":"The COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997;112:1514\u201321.","journal-title":"Chest"},{"key":"41_CR32","first-page":"902","volume":"8","author":"E Chrischilles","year":"2002","unstructured":"Chrischilles E, Gilden D, Kubisiak J, Rubenstein L, Shah H. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am J Manag Care. 2002;8:902\u201311.","journal-title":"Am J Manag Care"},{"key":"41_CR33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pupt.2014.08.010","volume":"31","author":"D Singh","year":"2015","unstructured":"Singh D, Zhu CQ, Sharma S, Church A, Kalberg CJ. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study. Pulm Pharmacol Ther. 2015;31:85\u201391.","journal-title":"Pulm Pharmacol Ther"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-017-0041-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T13:48:37Z","timestamp":1569073717000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41030-017-0041-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s41030-017-0041-7","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,24]]}}}